The Relevance of Clinical Trials and Real-World Data

At EADV 2026 | Date: Saturday, October 3, 2026 | Time: TBD

Austria Center Vienna, Bruno-Kreisky-Platz 1, 1220, Vienna, Austria

PROGRAM CHAIRS

PROGRAM DESCRIPTION 

This session will examine how clinical trials and real-world evidence are shaping current and future care in atopic dermatitis. Faculty will review practical lessons from trial setup and late-phase study design, address challenges in pediatric research, and discuss how emerging data on biomarkers, disease heterogeneity, treatment patterns, safety, and regulatory-grade evidence can help bridge mechanistic insights with clinical decision-making.

LEARNING OBJECTIVES

At the end of the session, participants will be able to:

1. Describe key operational and design considerations involved in setting up and conducting late-phase clinical trials in atopic dermatitis.
2. Compare the strengths and limitations of clinical trial data and real-world evidence when evaluating treatment effectiveness and safety, including in pediatric populations.
3. Identify how biomarkers, phenotype-endotype correlations, and high-quality registry or real-world datasets may support patient stratification and treatment decision-making in atopic dermatitis.

AGENDA

Welcome from the IEC
Alan Irvine, MD DSc | IEC President | Trinity College Dublin, Children’s Health
Dublin, Ireland

Program overview
Thomas Bieber, MD, PhD, MDRA | IEC Councilor | Professor of Dermatology and Allergy, Ludwig-Maximilians University, Munich, Germany.
Kenji Kabashima, MD PhD | IEC Director | Professor, Department of Dermatology | Kyoto University Graduate School of Medicine | Kyoto, Japan

Part 1: Clinical Trials: What Have We Learned?

From Protocol to Patient: Mastering the Logistics of Clinical Trial Setup
Robert Bissonnette, MD FRCPC MSc | CEO and Medical Director, Indero (formerly Innovaderm) | IEC Past President | Montreal, QC, Canada

Designing Late-Phase Trials
Andy Blauvelt, MD, MBA | IEC Councilor | Blauvelt Consulting, LLC

Children First? The Complex Reality of Pediatric Trials in Atopic Dermatitis
Speaker TBA

Part 2: Real-World Data: Effectiveness, Safety, and Treatment Patterns

From Cytokine Circuits to Clinical Outcomes: How Clinical Trials Have Redefined Atopic Dermatitis
Kenji Kabashima, MD PhD | IEC Director | Professor, Department of Dermatology | Kyoto University Graduate School of Medicine | Kyoto, Japan

Q & A | All Previous Speakers, Parts 1-2

BREAK

Part 3: Bridging Trials and Real-World Evidence

Treatment Success in Early Atopic Dermatitis Through Predictive Biomarkers and Deep Remission
Speaker TBA

Phenotype-endotype correlation: Translational Aspects Bridging Mechanistic Insights and Clinical Stratification
Kilian Eyerich, MD PhD | IEC Councilor |

The long and challenging way to “regulatory grade” data in registries and real-world evidence
Thomas Bieber, MD, PhD, MDRA | IEC Councilor | Professor of Dermatology and Allergy, Ludwig-Maximilians University, Munich, Germany

Q & A | All Previous Speakers, Part 3

Program summary & concluding remarks
Thomas Bieber, MD, PhD, MDRA | IEC Councilor | Professor of Dermatology and Allergy, Ludwig-Maximilians University, Munich, Germany.
Kenji Kabashima, MD PhD | IEC Director | Professor, Department of Dermatology | Kyoto University Graduate School of Medicine | Kyoto, Japan

Please check back with us for updates.

This educational symposium presented by the IEC is offered at no cost to attendees.